close icon

Dark Clouds on Humana’s Horizon

It was a nice run, but Humana’s upside potential is limited from now on

The last eight years must have been great for Humana Inc. investors. From its March 2009 bottom at $18.57, the stock has gained over $200 a share or roughly 1077%. That is 36.2% compounded annually, which is a great return in anybody’s book. Humana closed slightly below its all-time high yesterday, which is a strong indication that investors are felling as if the uptrend is going to last forever. But is it? Of course not and our job is to try to determine what is left of it by applying the Elliott Wave Principle to Humana’s weekly price chart given below.
humana weekly chart
The chart above shows the stock’s entire rally since 2009. According to the theory, a five-wave impulse is what every trend is made of. Humana seems to be confirming that by drawing a clear impulsive pattern, whose wave V is still developing. Unfortunately, every five-wave sequence is followed by a three-wave correction of similar magnitude in the opposite direction. This means that once wave V exceeds the top of wave III, a major bearish reversal would be likely. In our opinion, investors should not get too carried away by Humana’s impressive performance in the last eight years. The support of wave IV near $150 a share is a reasonable target of the anticipated decline. It looks like the bull party is approaching to its end and in the stock market, latecomers always suffer the most.



Stay informed with our newsletter

Latest Elliott Wave analysis on different topics delivered to you weekly.

Privacy policy
You may also like:

Bristol-Myers Stock Pattern Triggers a 37% Surge

Bristol-Myers Squibb and Celgene are expected to merge into a single company before the end of the year. The deal will create the fifth largest pharmaceutical company in the world with sales of approximately $42 billion in 2019. Bristol-Myers fell sharply after the deal was announced in early-January. In late-April, the stock was still in…

Read More »

Home Capital: Third Wave Lifts Stock 140% in 2019

Home Capital Group is up 17.4% in Toronto today following the company’s third quarter financial report. The mortgage lender beat analysts’ earnings expectations and delivered improvements in other areas, too. In total, HCG is up ~140% in 2019. But things didn’t look so rosy at the beginning of the year. The stock was hovering in…

Read More »

Walgreens: Did the Market Foresee that KKR Offer?

Anyone who’s been in Elliott Wave analysis long enough has noticed how often some external factor “makes the price move” in the direction the analysis had identified much earlier. We’ve seen it happening in crypto, we’ve seen in happening in stock indices. Now, it happened with Walgreens stock. Walgreens jumped on November 5th after CNBC…

Read More »

SERV Stock Gave a Warning Before Crashing 40%

The last three weeks have been tough on ServiceMaster shareholders. SERV stock was hovering around $56 a share as October went into its final third. But when the company announced its preliminary Q3 results on October 22nd, all hell broke loose. Apparently, Wall Street didn’t like what it saw, which resulted in a swift and…

Read More »

Expedia Disappointed. Elliott Wave Analysis Did Not

Expedia stock is down 25% today after the company’s Q3 results missed expectations. GAAP EPS fell 57 cents short of analysts’ estimates. The revenue figure was anticipated to be $10 million higher than reported, as well. On top of that, Expedia cut its full-year guidance which annoyed Wall Street even more. That is the official…

Read More »

SEIC Stock Can Lose Half its Value in a Recession

SEI Investments provides investment management, processing and platforms for private banks, institutional investors and investment advisors and managers. With a market cap of roughly $9.4 billion, the company is in the mid-cap category, which is generally thought to offer some of the best growth potential opportunities. But is SEIC stock a good choice around $62…

Read More »

DexCom ‘s Wall Street Darling Status is in Danger

In previous articles, we’ve discussed numerous stocks, which brought their investors great returns in the past decade. Today’s material will focus on one that beats them all. DexCom – a medical device company, headquartered in San Diego, California. In November 2008, during the throes of the Financial Crisis, DXCM stock plunged to as low as…

Read More »

More analyses